Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin in Biliary Tract and Gallbladder Cancer
NCT00123825Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in biliary tract cancer (BTC) and gallbladder cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate. Started Jul 2002; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
biliary tract cancer (BTC)gallbladder cancer
Beyond the preview
Go deeper on NCT00123825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123825.